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Wicker, Christina Ann. M.S., Department of Neuroscience, Cell Biology, and 
Physiology, Wright State University, 2008.   Sensitization to TRAIL Induced Apoptosis 
in K-Ras 12 Mutant Pancreatic Cancer Cells by BITC. 
 
 
Pancreatic adenocarcinoma is an aggressive cancer with a greater than 95% 
mortality rate and short survival after diagnosis.  Chemotherapeutic resistance hinders 
successful treatment.  This resistance is associated with mutations within codon 12 of the 
K-Ras gene (K-Ras 12), which is present in over 90% of all pancreatic adenocarcinomas.  
Codon 12 mutations maintain Ras in a constitutively active state leading to continuous 
cellular proliferation.  
 Our study determined if TRAIL resistance in pancreatic adenocarcinomas with K-
Ras 12 mutations could be overcome by first sensitizing the cells with Benzyl 
isothiocyanate (BITC).  BITC is a component of cruciferous vegetable extracts and a cell 
cycle inhibitor.  BxPC3, MiaPaCa2, and Panc-1 human pancreatic adenocarcinoma cell 
lines were examined for TRAIL resistance.  Our studies show BITC-induced TRAIL 
sensitization by the activation of caspases 8, 9 and 3 as well as their respective substrates 
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I.  INTRODUCTION 
Pancreas 
The pancreas is a small finger-like organ located behind the stomach.  It a vital 
organ and has both endocrine and exocrine functions.  Endocrine functions occur within 
the islets of Langerhans where alpha cells produce glucagon, beta cells produce insulin 
and delta cells produce somatostatin (1). These products are integral in maintaining blood 
glucose homeostasis.  Glucagon facilitates the breakdown of glycogen that the liver 
stores to increase blood glucose levels and insulin is responsible for glucose uptake into 
cells.  Somatostatin is an inhibitory hormone with a wide variety of functions including 
inhibition of hormones associated with gastric motility and can also inhibit insulin and 
glucagon release (2).  Exocrine functions of the pancreas are in relation to food digestion.  
Bicarbonate is secreted by centroacinar cells into the small intestine to neutralize stomach 
acids (1).  Within the pancreatic acini, digestive enzymes are produced.  Inactive 
proteases such as trypsinogen and chymotrypsinogen are necessary for protein digestion.   
The pancreas also secretes pancreatic lipase for digestion of fats and pancreatic amylase 
for starch digestion (1).  All of these functions are critical for normal digestion and blood 
glucose homeostasis and disruption of these functions such as by pancreatic cancer lead 





Pancreatic cancer is the fourth leading cause of cancer related deaths in the United 
States (3,4).  It is estimated that in 2008, there will be 37,680 new cases of pancreatic 
cancer (3,4).  Incidence is nearly equal in both the female and male population (3).  Risk 
factors for pancreatic cancer include age, obesity, diabetes, hereditary chronic 
pancreatitis, and exposure to carcinogens, such as those released during smoking (5,6).  
Pancreatic cancer includes exocrine, neuroendocrine and adenocarcinoma.  
Adenocarcinoma is the most common and has the least favorable prognosis (7,8).  
In general, patients remain asymptomatic until wide spread metastasis has 
occurred.  Symptoms that do appear later include fatigue, weight loss, jaundice, back 
and/or abdominal pain (3).  There are three usual treatment options including surgery, 
radiation, and chemotherapy.  Surgical options include pancreatic resection or complete 
pancreatectomy; however, these options are only available to 20% of patients (9).  
Pancreatic adenocarcinomas are largely resistant to both radiation and chemotherapy.  
Current chemotherapeutic options include the use of DNA replication inhibitors such as 
Gemcitabine, 5-Fluorouracil (5-FU) as well as platinum-based drugs including Cisplatin, 
which also inhibit DNA replication (10).  Other therapies include inhibition of growth 
factors associated with tumor growth, such as epidermal growth factor (EGF) and 
vascular endothelial growth factor (VEGF) but these show limited effectiveness to date 
(10).  The combination of late detection and chemotherapeutic resistance in pancreatic 





Over ninety percent of pancreatic adenocarcinomas harbor a mutation within 
codon 12 of the K-Ras gene (11,12).  Although other mutations, such as p53, p16, and 
SMAD 4 have been reported in pancreatic adenocarcinomas, K-Ras mutations have been 
shown to be an initiating factor in the formation of pancreatic cancers (12).  Ras regulates 
migration, cytoskeletal formation, apoptosis, and cellular proliferation amongst other 
functions, predominantly through Erk 1/2 signal transduction pathways (13-15).  The Ras 
family includes three Ras isoforms Harvey (H-Ras), Kirsten (K-Ras) and Neuroblastoma 
(N-Ras) (16-18).  Differences between these genes are largely in the C-terminal region 
(19,20).  All Ras isoforms are involved in signaling through MAPK and AKT pathways, 
although some isoform-specific signaling has been reported (21).    
 Ras is a G protein that cycles between an inactive GDP-bound state and an active 
GTP-bound state  (Fig. 1) (19).  The Guanine-Nucleotide exchange factor (GEF) assists 
in the dissociation of GDP allowing GTP binding and thus activating Ras (22).  GTPases 
such as the intrinsic GTPase within the Ras structure and Ras-GAP hydrolyse GTP to 
GDP and thus inactivates Ras (23,24).  Mutations within codon 12 of K-Ras hinder this 
endogenous GTPase activity, thereby maintaining Ras in its GTP-bound active state (17).  
Constitutive activation of Ras leads to continuous cellular proliferation. 
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Figure 1.  Ras cycling and signaling.  Ras cycles between an inactive GDP bound state 
and an active GTP bound state.  This cycling is facilitated by GEF and GTPases.    
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Previous reports have shown that BITC can inhibit cell cycle progression and 
initiate pancreatic cancer cell death (25).  BITC is a cruciferous vegetable extract and is a 
member of the isothiocyanate family.  Isothiocyanates have been found to be protective 
against carcinogenesis by several mechanisms (25,26).  These include modulation of 
phase I and II p450 enzymes and the cell cycle.  Cytochrome P450, a phase I enzyme, has 
also been implicated in carcinogen activation.  BITC has been shown to inhibit P450 and 
its role in carcinogenesis (27).  Cytochrome P450 is involved in oxidative metabolism, 
which may lead to the formation of ROS (28, 29).  ROS have been implicated in 
tumorogenesis through DNA damage, epigenetic changes, and supporting angiogenesis 
needed for tumor growth (30-32).  BITC has been shown to induce Phase II enzymes 
including glutathione transferase, which can detoxify hazardous metabolites that may 
initiate carcinogenesis (27,29,33).  BITC has an electrophilic structure and it is attracted 
to nucleophiles such as GSH, which are at high intercellular levels (Fig. 2) (34).  
Isothiocyanates have been implicated in mitochondrial membrane damage, which can 
initiate the intrinsic mitochondrial cell death pathway (35).  The third method against 
carcinogenesis involves BITC increasing G2/M cell cycle arrest by decreasing Cdk1, 
CyclinB1, and Cdc25C protein levels (25,36-40).  
 7
Figure 2.  BITC structure.  This figure illustrates the structure of BITC.  The –N=C=S 
is responsible for the compounds electrophilic properties, meaning the compound is 
attracted towards negatively charged compounds. 
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K-Ras 12 mutations have been associated with chemotherapeutic resistance to 
TRAIL-induced apoptosis.  TRAIL (TNF related apoptosis-inducing ligand) is a novel 
and potential chemotherapeutic agent.  TRAIL is both membrane bound and secreted.  It 
is produced in nearly all antigen presenting cells (APC) (41-43).  There is debate over 
TRAIL's normal physiological role in humans but some propose it as a guard against 
tumorogeneis (44).  
 TRAIL is a member of the TNF cytokine family.  Five TRAIL receptors 
including 2 decoy receptors DCR1 and DCR2, two death receptors DR4 and DR5 and an 
osteoprotogerin (OPG) receptor exist.  The decoy receptors bind to TRAIL but lack the 
intercellular signaling needed to induce cell death.  It has been proposed that these 
receptors act to bind up TRAIL and protect the tissues from death (45).  Cell death can be 
induced when TRAIL binds to DR4 and DR5 receptors.  OPG binds to TRAIL but does 
not induce cell death as it lacks the needed intracellular signaling.  It is thought to also act 
as a decoy receptor in the adult.  TRAIL death receptors are highly expressed on 
transformed cells but generally absent on most normal cells (46).  The cytotoxic effects 
of TRAIL are pronounced on cancerous cells but leave most noncancerous tissues 
unaffected (47,48).  TRAIL has been shown to induce apoptosis in sensitive cells (49).  
Previous studies have attempted to use TRAIL as a chemotherapeutic agent in human 





Apoptotic Pathway  
Two major pathways, the extrinsic (death receptor) pathway and the intrinsic 
(mitochondrial) pathway regulate apoptosis (Fig. 3)(46).  The extrinsic cell death 
pathway begins with external death receptors on the cell surface.  When ligands such as 
TNF alpha, Fas or TRAIL have bound to their specific receptor, intercellular signaling 
occurs through recruitment of adaptor proteins (51,52).  Recruitment of adaptor proteins 
induces caspase 8 cleavage and activation.  Caspase 8 can cleave effector caspase 3 
inducing apoptosis directly (53).  Alternatively, caspase 8 can trigger the activation of the 
intrinsic cell death pathway by cleavage of Bid, a proapoptotic protein (54).  Truncated 
Bid (t-Bid) is capable of interacting with other pro-apoptotic proteins leading to loss of 
mitochondrial membrane integrity, which has been shown previously to release 
cytochrome C (35).  Cytochrome C release is associated with the activation of caspase 9 
(55).  Activated caspase 9 can lead to cleavage and activation of effector caspase 3 and 





Figure 3. Extrinsic and intrinsic pathways of apoptotic death.  This figure depicts 
signaling of the extrinsic and intrinsic apoptotic pathway and its key components. 
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 In pancreatic cancer, K-Ras 12 mutations have been correlated to increased 
resistance to chemotherapeutic agents including TRAIL (61).  These mutations cause Ras 
to remain in its active GTP-bound state causing continual cellular proliferation (17).  
BITC is capable of inducing cell cycle arrest in human pancreatic cancer cells (25,63).  
Pretreatment of cells with BITC to inhibit Ras activity may restore sensitivity to TRAIL. 
 
Focus of Study 
  BxPC3, MiaPaCa2, and Panc-1 cell lines were selected because they represent 
the most common mutations found in human pancreatic adenocarcinomas (Table 1) 
(62,64,65).  BxPC3 cells, isolated from human pancreatic adenocarcinoma, are 
tumorigenic but are wildtype for codon 12 K-Ras.  Panc-1 cells, harbor a glycine to 
aspartate amino acid change within codon 12, and MiaPaCa2 cells, a glycine to cysteine 
amino acid change were also studied.  We hypothesize that BITC will sensitize mutant K-
Ras 12 human pancreatic adenocarcinoma cell lines to TRAIL-induced apoptosis.  Our 
results indicate that BITC sensitizes chemotherapeutically resistant human pancreatic 




Table 1.  K-Ras 12 Mutations in BxPC3, MiaPaCa2, and Panc-1 Human Pancreatic 
Cancer Cell Lines 
Cell Line K-Ras 12 Nucleotide Change Amino Acid Change References 
BxPC3 GGT None; Gly (61,62)  
MiaPaCa2 GGT TGT Gly Cys (61,62) 
Panc-1 GGT GAT Gly Asp (61,62) 
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Significance 
 Pancreatic cancer is one of the top 5 deadliest cancers in the U.S. and is virtually 
incurable  (3).  Current treatments are mostly palliative in nature and patients are not 
expected to live much more than 6 months after diagnosis.  K-Ras 12 mutations, present 
in over 90% of adenocarcinomas, are heavily correlated with chemotherapeutic resistance 
(11,12,66).  This resistance is a major component of the greater than 95% mortality rate 
(3,4).  Our study demonstrates one method of combating chemotherapeutic resistance 





II.   MATERIALS AND METHODS 
 
Materials 
 Panc-1 and BxPC3 cells were purchased from ATCC.  Dr. B. Weissman of 
University of North Carolina, Chapel Hill School of Medicine kindly provided MiaPaCa2 
cells.  Goat anti-rabbit (W401B) and goat anti-mouse (W402B) HRP-conjugate 
secondary antibodies were purchased from Promega.  The primary antibodies used were 
rabbit polyclonal anti-XIAP (Cell Signaling Cat # 2042), rabbit polyclonal PARP (Cell 
Signaling Cat # 9541S), mouse monoclonal caspase 8 (Cell Signaling Cat # 9746), active 
caspase 9 mouse monoclonal (Upstate Biotech Cat # 05-572), and Bid rabbit polyclonal 
(Cell Signaling 2002).  Pan actin mouse monoclonal was kind gift from Dr. J. Lessard at 
Cincinnati Childrens Hospital.  Active caspase 3 rabbit polyclonal antibody was a kind 
gift from Dr. K. Tomaselli at Idun Pharmaceuticals.  For apoptotic death quantification, 
the Roche Cell Death ELISA Assay was used (Roche Cat # 1 774 425).  Human 
recombinant TRAIL was purchased from R&D Systems (Cat # 375-TEC).  BITC was 
purchased from Sigma-Aldrich (Cat # 252492).  Anti-fas antibody was purchased from 







 BxPC3, MiaPaCa2, and Panc1 cells were maintained in RPMI 1640 with L-
glutamine, supplemented with 5% heat-inactivated fetal bovine serum and 1% 
antibiotic/antimycotic.  Cells were maintained at 5% CO2 and 37° C.  All cell lines were 
maintained at 1X105 cells/ml. 
 
Treatment Protocol 
  For collection of whole cell lysates used in Western blot analysis, cells were 
plated at 2X105 cells/ml and allowed to sit for overnight.  The next evening, media was 
changed to 5 ml RPMI 1640 with 5% FBS and 1 % antibiotic/antimycotic.  Vehicle and 
TRAIL alone groups were treated with 5 μl 50 % DMSO/ddH2O.  BITC and BITC with 
TRAIL groups were treated with a final concentration of 5 μM BITC overnight.  The 
following morning vehicle and BITC groups were treated with 5 μl 0.1% BSA.  TRAIL 
and BITC combined with TRAIL groups were treated with a final concentration of 10 
ng/ml TRAIL for 6 hours.  Total treatment time with BITC was 24 hours.  Cells were 
then collected for whole cell lysates. 
 As a positive control, Jurkat cultures were treated at 1X106 cells/ml with 100 
ng/ml anti-Fas antibody for 4 hours or 1 μg/ml Actinomycin D for 4 hours and whole cell 







 Cell lysates were collected in CHAPS buffer (50 mM PIPES pH 6.5, 2 mM 
EDTA pH 8.0, 0.1 % CHAPS) with proteosome inhibitor, sonicated, and centrifuged at 
12,000 rpm for 10 minutes at 4°C.  Protein content was determined using the Bradford 
assay (67).  Cell lysates were treated with Reducing Sample Buffer, and heat-treated for 5 
minutes at 100°C.  Proteins were resolved on an SDS polyacrylamide gel via 
electrophoresis (57-60).  Separated proteins were subsequently transferred onto PVDF 
membrane in Western transfer buffer overnight at 0.1 A (68).  Proteins were visualized 
using Ponceau S staining and the membrane was then blocked at room temperature for 
one hour in milk blocking buffer (1X PBS, 5% (w/v) non-fat dry milk, and 0.05 % 
Tween-20) for caspase 3 and 9 and Bid.  Blots were blocked in TBS milk blocking buffer 
for XIAP, PARP, and caspase 8.  Blots were rinsed in 1X PBS or 1XTBS containing 
0.5% Tween-20.  XIAP, PARP, caspase 8 and 9 were incubated with the primary 
antibody overnight at 4°C.  Actin was incubated at (1:16,000) for 40 minutes at room 
temperature (RT) and active caspase 3 at (1:4,000) for 2 hours at RT.  Primary antibodies 
include Bid (1:1,000), XIAP (1:1,000), cleaved PARP (1:1,000), active caspase 8 
(1:1,000) and active caspase 9 (1:1,000).  Blots were incubated with secondary antibody 
for 1.5 hours at room temperature.  Secondary antibodies included goat anti-rabbit 
(1:50,000) and goat anti-mouse (1:10,000).  For actin, goat anti-mouse was used at 
(1:20,000).  Blots were then incubated following the manufacturer’s recommendations 
with Pierce SuperSignal® West Pico Chemiluminescent Substrate and exposed to film or 
imaged on Fugi using LAS 3000 software.    
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Cell Death ELISA Assay 
 Roche Cell Death ELISA Assay kit was used after treatment of TRAIL to detect 
increase in oligosomal fragments that are indicative of apoptosis.  This assay uses a 
sandwich ELISA method, whereby streptavadin-coated plates are pretreated with an anti-
histone antibody.  Treated lysate is applied the plates are then rinsed to remove any 
unbound DNA.  Anti-DNA-peroxidase antibody is then applied to bind to the bound 
oligonucleosomal fragments.  The plates were then treated with ABTS substrate, which 
reacts with the peroxidase on the anti-DNA antibody and produces a blue colorimetric 
reaction.  This reaction was spectrophotometricaly measured at wavelength of 405 nm 
and 490 nm to record background fluorescence.  Background fluorescence was subtracted 
from the fluorescence at 490 nm and treatment groups were normalized to the vehicle 
control. 
 For Cell Death ELISA analysis, cells were plated at 2X105 in 2 mls of media in 6 
well plates.  Cells were incubated overnight before treatment.  Vehicle and TRAIL alone 
groups were treated with 2 μl of 50% DMSO/ddH2O for a final concentration of 
0.05%DMSO.  BITC combined and BITC with TRAIL groups were pretreated with a 
final concentration of 5 μM BITC overnight.  The following morning vehicle, and BITC 
groups were treated with 2 μl 0.1% BSA and TRAIL and BITC combined with TRAIL 
groups were treated with a final concentration of 10 ng/ml TRAIL for 6 hours.  Total 
treatment time with BITC was 24 hours.  Cells were then collected for analysis with the 
Cell Death ELISA assay following the manufacturer’s protocol. 
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Cell Counting for ELISA Normalization 
 Cells were trypsinized and resuspended in saved media.  Cells were centrifuged 
for 500 RPM for 5 minutes.  Supernatant was discarded and pellet was resuspended in 1 
ml 1X PBS.  Cells were counted using trypan blue exclusion with a hemocytometer.  
Four fields were counted 6 times and the cell counts averaged.  This procedure was 
repeated for three independent trials for each cell line.  Percent inhibition of proliferation 
compared to vehicle was calculated.  These values were then used to normalize the Cell 
Death ELISA results. 
 
Statistical Analysis 
 Statistical analysis was done using a one-way ANOVA.  Results were considered 
to be statistically significant at p value ≤ 0.05.  All experiments were done independently, 










III.  RESULTS 
 
Determination of optimal effective concentration of TRAIL  
 Resistance to TRAIL-induced apoptosis has previously been shown in pancreatic 
cancer cells (49).  To determine the optimal effective concentration of TRAIL needed to 
induce apoptosis, we first treated Panc-1 cells with increasing concentration at 0, 1, 10, 
and 100 ng/ml TRAIL for 6 hours (Fig. 4).  TRAIL-induced apoptosis was evaluated 
using the Cell Death ELISA assay.  Increasing amounts of apoptosis was observed with 
increasing concentrations of TRAIL.  There was no significant increase in apoptosis with 
1 ng/ml TRAIL compared to the vehicle treated cells.  A significant 1.5 fold increase in 
apoptotic death was observed with 10 ng/ml TRAIL when compared to the vehicle alone 
and the 100 ng/ml TRAIL showed a 1.95 fold increase in cell death (p < 0.05).  Since a 
significant increase in apoptosis compared to control was observed at 10 ng/ml TRAIL 
and as there was no significant difference in apoptotic death between 10 ng/ml TRAIL 
and 100 ng/ml TRAIL, 10 ng/ml TRAIL was chosen for all further studies. 
 22
Figure 4.  Determination of optimal TRAIL concentration in Panc-1 cells.  Panc-1 
cells were plated 1X105 cells/ml.  Cells were treated with 0, 1, 10, and 100 ng/ml TRAIL 
for 6 hours and analyzed by Cell Death ELISA assay.  The results are represented by fold 
increase in apoptosis compared to vehicle.  Error bars represent standard deviation.  * 













Determination of optimal treatment time with TRAIL 
Next, we determined the optimum duration for TRAIL treatment.  Panc-1 and 
BxPC3 cells were treated with 10 ng/ml TRAIL for 6, 15 and 24 hours and apoptosis was 
analyzed using the Cell Death ELISA assay (Fig. 5).  When compared to the vehicle there 
was a 7.04 fold increase in cell death at 6 hours in BxPC3 cells, at 15 hours there was a 
4.53 fold increase in cell death and at 24 hours there was a 3.76 fold increase in cell 
death.  In Panc-1 cells, at 6 hours there was a 2.76 fold increase, at 15 hours there was a 
0.96 fold increase in cell death, and at 24 hours there was a 1.05 fold increase in cell 
death.  Higher levels of TRAIL-induced apoptosis were observed in wildtype K-Ras 12 
BxPC3 cells, than seen in K-Ras 12 mutant Panc-1 cell line.  The highest fold increase in 
apoptotic death (7 fold compared to the vehicle) was observed at 6 hours and this time 
point was chosen for all further experiments.  
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 Figure 5.   Determination of optimal treatment duration with TRAIL in BxPC3 and 
Panc-1 cell lines.  BxPC3 and Panc-1 cells were plated at 1X105 cells/ml.  Cells were 
treated with 10 ng/ml TRAIL for 0, 6, 8, 15 and 24 hours and analyzed using Roche Cell 
Death ELISA.  The results are represented by fold increase in apoptosis compared to 
vehicle.  Error bars represent standard deviation.  * Denotes significance to p ≤ 0.05 
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 Apoptotic induction in BxPC3, MiaPaCa2, and Panc-1 cell lines  
BITC is known to induce cell cycle arrest in human pancreatic cancer cells 
(25,26,37,39).  We analyzed the effect of BITC on TRAIL-induced apoptosis in BxPC3, 
MiaPaCa2, and Panc-1 cells by the Cell Death ELISA assay (Fig. 6).  Cells were treated 
with vehicle, BITC alone, TRAIL alone or BITC in combination with TRAIL.  The Cell 
Death ELISA results indicated BITC alone caused a modest, nonsignificant increase in 
apoptosis in BxPC3, MiaPaCa2, and Panc-1 cell lines with a 1.5-3 fold increase in 
apoptosis.  Baseline TRAIL sensitivity in the three cell lines was determined.  BxPC3 and 
MiaPaCa2 cells were the sensitive to TRAIL-induced apoptosis with a 8-fold increase in 
apoptosis compared to vehicle.  Panc-1 cells were the most resistant with only a 1.6 fold 
increase in apoptosis with TRAIL alone.  
 
Inhibition of cell growth in BxPC3, MiaPaCa2, and Panc-1 cell lines 
Because BITC is a known cell cycle inhibitor, the fold change in cell death was 
normalized to the cell number to accurately reflect the degree of apoptosis (Fig. 7, Fig. 
8).  Cell counts were performed to determine effects of treatment on cellular proliferation 
(Fig. 7).  In BxPC3 cells, BITC led to a 46% reduction in cell number.  TRAIL caused a 
14% reduction and BITC combined with TRAIL caused a 49% reduction in cell number.  
In MiaPaCa2 cells, BITC led to a 34% decrease in cell number.  TRAIL caused a 7% 
reduction and BITC combined with TRAIL caused a 54% reduction in cell number.  
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Figure 6.  Quantification of apoptotic death in BxPC3, MiaPaCa2, and Panc-1 cell 
lines.  BxPC3, MiaPaCa2, and Panc-1 cells were plated at 1X105/ml in RPMI 1640 with 
5 % FBS.  Cells were treated with vehicle (V), 5 μM BITC for 24 hours (B), 10 ng/ml 
TRAIL (T) for 6 hours or both B and T (BT). Cells were treated with 10 ng/ml TRAIL 
and analyzed by Cell Death ELISA.  Cell Death ELISA results are represented by fold 
increase in apoptosis compared to vehicle.  Error bars represent standard deviation.  * 
Denotes significance to p ≤0.05  
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Figure 6.  
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Figure 7.  Inhibition of cell growth in BxPC3, MiaPaCa2, and Panc-1 cell lines.  
BxPC3, MiaPaCa2, and Panc-1 cells were plated at 1X105/ml in RPMI 1640 with 5 % 
FBS.  Cells were treated with vehicle (V), 5 μM BITC for 24 hours (B), 10 ng/ml TRAIL 
(T) for 6 hours or both B and T (BT).  Cell counts were performed using trypan blue for a 
minimum of four fields, six times and averaged to determine the effects of treatments on 
cell growth.  * Denotes significance to p ≤0.05.  # Denotes significance to p ≤ 0.05 
between T and BT. 
 
 31
Figure 7.     
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Figure 8.  Normalized Apoptotic Induction in BxPC3, MiaPaCa2, and Panc-1 cell 
lines.  BxPC3, MiaPaCa2, and Panc-1 cells were plated at 1X105/ml in RPMI 1640 with 
5 % FBS.  Cells were treated with vehicle (V), 5 μM BITC for 24 hours (B), 10 ng/ml 
TRAIL (T) for 6 hours or both B and T (BT).  In Fig. 1a and b, cells were collected and 
analyzed using Roche Cell Death ELISA following the manufacturer's recommended 
protocol.  The results are represented by fold increase in apoptosis compared to vehicle 
and represent a minimum of 3 independent trials.  These data represent Cell Death 
ELISA results after normalization to cell count.  Percent decrease in cell numbers 
compared to vehicle was calculated and used to normalize the Cell Death ELISA results.  
Error bars represent standard deviation.  * Denotes significance to p ≤0.05 # Denotes 
significance to p ≤ 0.05 between T and BT. 
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Figure 8.  
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In Panc-1 cells, BITC led to a 25% decrease, whereas TRAIL alone caused a 12% 
decrease and BITC combined with TRAIL caused a 37% decrease in cell number (Fig. 
6). 
 
Normalized Apoptotic Induction in BxPC3, MiaPaCa2, and Panc-1 cell lines 
Higher amounts of cell death were observed in all cells treated with TRAIL alone 
when compared with TRAIL combined with BITC.  BITC is a known cell cycle inhibitor, 
and believed to arrest cells in the G2/M phase.  To address inconsistencies that may arise 
during Cell Death ELISA assay due to a decrease in cell numbers, we normalized the Cell 
Death ELISA assay results to cell number to accurately reflect the degree of apoptosis 
(Fig. 8).  With cell number taken into consideration, the normalized Cell Death ELISA 
showed a 3.84 fold increase in apoptosis in BxPC3 upon treatment with BITC alone, a 
8.65 fold increase was observed with TRAIL alone, and a 12.39 fold increase was seen in 
BxPC3 cells treated with BITC combined with TRAIL compared to vehicle.  MiaPaCa2 
showed a 2.08 fold increase in apoptosis upon treatment with BITC, a 9.12 fold increase 
with TRAIL alone, and a 11.72 fold increase with BITC combined with TRAIL 
compared to vehicle.  Panc-1 cells showed a 1.49 fold increase in apoptosis upon 
treatment with BITC, a 1.82 fold increase with TRAIL alone, and a 3.45 fold increase 
with BITC combined with TRAIL compared to vehicle.  BITC combined with TRAIL 
produced a significant increase in apoptotic cell death compared to TRAIL alone in all 




Activation of caspase 8 in BxPC3, MiaPaCa2, and Panc-1 cell lines  
 Western blot analysis was performed to determine the apoptotic pathways 
involved in the BITC and TRAIL-induced apoptosis in pancreatic adenocarcinoma cells.  
BxPC3, MiaPaCa2, and Panc-1 cells were treated with vehicle, BITC, TRAIL, or BITC 
combined with TRAIL and examined for activation of extrinsic cell death pathway as 
suggested by caspase 8 cleavage (Fig. 9)(35,46,54).  In BxPC3 cells, vehicle alone had no 
effect on caspase 8.  BITC alone led to a 6.84 fold decrease in the 57 kDa proform and a 
0.5 fold increase in the 43 kDa cleaved caspase 8 compared to vehicle.  Treatment with 
TRAIL alone showed a 5.15 fold increase in cleavage of the inactive, 57 kDa proform of 
caspase 8 and produced a 3.27 fold decrease in proform levels.  A combination of BITC 
with TRAIL showed further loss of the intact proform with a 3.66 fold decrease 
compared to vehicle while cleaved 43 kDa form levels remained similar.  In MiaPaCa2 
cells, there was no cleavage of caspase 8 with vehicle.  BITC alone led to a 1.13 fold 
decrease in caspase 8 proform and a 0.70 fold increase in cleaved caspase 8 levels 
compared to vehicle.  TRAIL alone produced a 9.28 fold decrease of the caspase 8 
proform with a 9.18 fold increase in caspase 8 cleavage.  Combination of BITC with 
TRAIL caused led to a 3.55 fold decrease in caspase 8 proform and a 20.98 fold increase 
in cleaved caspase 8 levels.  In Panc-1 cells, BITC alone produced a 0.83 fold decrease in 
caspase 8 proform levels and a 0.46 fold increase in cleaved caspase 8.  TRAIL alone 
produced a 1.12 fold decrease in proform levels and a 3.52 increase in cleaved caspase 9.  
BITC combined with TRAIL produced a 3.14 fold decrease in caspase 8 levels and a 5.26 
increase in cleaved caspase 8 levels compared to vehicle.  BITC increased cleavage of 
procaspase 8 in BxPC3 and Panc-1 cell lines compared to vehicle.  There were greater 
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Figure 9.   Caspase 8 activation in human pancreatic cancer cell lines.  Activation of 
caspase 8 in BxPC3, MiaPaCa2 and Panc-1 cell lines upon treatment with vehicle (V), 5 
μM BITC for 24 hours (B), 10 ng/ml TRAIL (T) for 6 hours or both 5 μM BITC and 10 
ng/ml TRAIL (BT).  Total treatment time was 24 hours.  Whole cell lysates were 
collected and separated by SDS-PAGE, and analyzed by Western blotting described in 
the Methods and Materials.  The blot was probed with active caspase 8 and reprobed with 
actin to ensure equal protein loading. 
 This graph illustrates relative fold change in caspase 8 proform and cleaved 
caspase 8 in A. BxPC3, B. MiaPaCa2 and C. Panc-1 cell lines upon treatment with 
vehicle, BITC alone, TRAIL alone, or BITC combined with TRAIL.  Fold change was 
determined using NIH image analysis of a Western blot for caspase 8 normalized to the 

















levels of cleaved caspase 8 in MiaPaCa2 and Panc-1 cells with combined treatment 
compared to TRAIL alone.   
 
XIAP cleavage in BxPC3, MiaPaCa2, and Panc-1 cell lines  
 X-linked inhibitor of apoptosis (XIAP) is a 53 kDa prosurvival protein and a 
direct target of caspase 8.  Reduction of intact XIAP was determined to further confirm 
caspase 8 activation.  NIH image was used to determine changes in levels of XIAP in 
BxPC3, MiaPaCa2 and Panc-1 cells upon treatment with vehicle, BITC alone, TRAIL 
alone and BITC combined with TRAIL (Fig. 10).  In BxPC3 cells, BITC alone produced 
a 1.12 fold decrease in XIAP compared to vehicle.  TRAIL alone produced a 1.77 fold 
decrease and BITC combined with TRAIL produced a 1.38 fold decrease in intact XIAP 
levels.  In MiaPaCa2 cells, BITC alone produced a 1.42 fold decrease in XIAP.  TRAIL 
alone produced a 1.15 fold decrease and BITC combined with TRAIL 2.89 fold decrease 
in intact XIAP levels.  In Panc-1 cells, BITC alone produced a 3.45 fold decrease in 
XIAP.  TRAIL alone produced a 1.02 fold decrease and BITC combined with TRAIL 
produced a 1.79 fold decrease in intact XIAP levels.  A 1.99 fold decrease was observed 
in Jurkat cells treated with anti-Fas antibody, which were used as a positive control for 
XIAP cleavage.  MiaPaCa2 and Panc-1 cell lines show increased XIAP cleavage upon 
with combined treatment with BITC and TRAIL compared to TRAIL alone.    
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 Figure 10.  XIAP cleavage in BxPC3, MiaPaca2, and Panc-1 cell lines.  XIAP 
cleavage in BxPC3, MiaPaCa2 and Panc-1 cell lines upon treatment with vehicle (V), 5 
μM BITC for 24 hours (B), 10 ng/ml TRAIL (T) for 6 hours or both BITC and TRAIL.  
Total treatment time was 24 hours.  Whole cell lysates were collected and separated 
through SDS-PAGE, and Western blotting was performed as described in the Methods 
and Materials.  The blot was probed with XIAP antibody and reprobed with pan actin to 
ensure equal loading. 
 This graph represents fold change in XIAP protein levels in BxPC3, MiaPaCa2, 
and Panc-1 cell lines upon treatment with vehicle, BITC alone, TRAIL alone, and BITC 
combined with TRAIL.  Fold change was determined using NIH image analysis of a 
Western blot for XIAP normalized to the vehicle.  NIH image was developed by NIH and 
can be found at http://rsb.info.nih.gov/nih-image/. 
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Figure 10.   
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Bid cleavage in BxPC3, MiaPaCa2 and Panc-1 cell lines  
 The death receptor pathway is known to activate caspase 8 and caspase 3 alone or 
trigger the intrinsic pathway via cleavage and activation of 22 kDa Bid (t-Bid) (35).  
BxPC3, MiaPaCa2, and Panc-1 cells treated with vehicle, BITC alone, TRAIL alone, or 
BITC combined with TRAIL were examined for Bid truncation (Fig. 11).  NIH image 
was used to analyze levels of Bid protein in BxPC3, MiaPaCa2, and Panc-1 cells upon 
treatment with vehicle, BITC alone, TRAIL alone and BITC combined with TRAIL.  In 
BxPC3 cells, BITC alone led to a 0.74 fold decrease in intact Bid compared to vehicle.  
TRAIL alone led to a 7.08 fold change and BITC combined with TRAIL led to a 8.91 
fold decrease in intact Bid levels.  In MiaPaCa2 cells, BITC alone produced a 1.28 fold 
decrease in Bid.  TRAIL alone produced a 18.32 fold decrease and BITC combined with 
TRAIL produced a 7.54 fold decrease in intact Bid levels.  In Panc-1 cells, BITC alone 
led to a 1.38 fold decrease in Bid levels.  TRAIL alone led to a 1.88 fold decrease and 
BITC combined with TRAIL led to a 3.14 fold change in intact Bid levels.  A 2.59 fold 
decrease was observed in Jurkat cells treated with anti-Fas antibody, which were used as 
a positive control for Bid cleavage.  In Panc-1 cell lines, increased Bid cleavage was 
observed upon treatment with BITC combined with TRAIL compared to TRAIL alone.    
 
Caspase 9 activation BxPC3, MiaPaCa2, and Panc-1 cell lines  
 Truncation of Bid has been shown to induce the intrinsic cell death pathway 
(35,56).  We sought to determine whether TRAIL combined with BITC could activate the 
intrinsic, mitochondrial cell death pathway.  BxPC3, MiaPaCa2 and Panc-1 cells were  
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Figure 11.  TRAIL-induced loss of intact Bid protein.  Bid cleavage in BxPC3, 
MiaPaCa2 and Panc-1 cell lines upon treatment with vehicle (V), 5 μM BITC 24 hours 
(B), 10 ng/ml TRAIL (T) for 6 hours or both B and T.  Total treatment time was 24 
hours.  Whole cell lysates were collected and separated through SDS-PAGE, and Western 
blotting was performed as described in the Methods and Materials.  The blot was probed 
with bid antibody and reprobed with pan actin used as a loading control 
 This graph illustrates relative fold change in intact Bid protein levels in BxPC3, 
MiaPaCa2 and Panc-1 cell lines upon treatment with vehicle, BITC alone, TRAIL alone, 
or BITC combined with TRAIL.  Fold change was determined using NIH image analysis 
of a Western blot for Bid normalized to the vehicle.  NIH image was developed by NIH 




Figure 11.     
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examined for the activation of caspase 9, initiator caspase for the intrinsic cell death 
pathway (Fig. 12)(35).  NIH image was used to determine the effects of vehicle, BITC 
alone, TRAIL alone and BITC combined with TRAIL on levels of the 46 kDa caspase 9 
proform and the 34 kDa cleaved form in BxPC3, MiaPaCa2 and Panc-1 cells.  In BxPC3 
cells, BITC alone led to a 1.03 fold decrease in caspase 9 proform compared to vehicle.  
TRAIL alone led to a 1.97 fold decrease and BITC combined with TRAIL led to a 1.08 
fold decrease in   caspase 9 proform levels.  BITC produced a 1.53 fold change in cleaved 
caspase 9 levels.  TRAIL alone produced a 4.26 fold change and BITC combined with 
TRAIL produced a 9.28 fold increase in cleaved caspase 9 levels.  In MiaPaCa2 cells, 
BITC alone led to a 1.47 fold decrease in caspase 9 proform levels.  TRAIL alone led to a 
1.81 fold decrease and BITC combined with TRAIL led to a 2.11 fold decrease in levels 
of caspase 9 proform.  BITC produced 0.13 fold change in cleaved caspase 9.  TRAIL 
alone produced a 0.5 fold change and BITC combined with TRAIL produced a 1.5 fold 
increase in cleaved caspase 9.  In Panc-1 cells, BITC led to a 1.61 fold decrease in 
caspase 9 proform levels compared to vehicle.  TRAIL alone led to a 2.02 fold decrease 
and BITC combined with TRAIL led to a 2.17 fold change in caspase 9 proform levels.  
BITC alone produced a 0.66 fold increase in cleaved caspase 9 compared to vehicle.  
TRAIL alone produced a 1.26 fold increase and BITC combined with TRAIL produced 
2.93 fold increase in cleaved caspase 9 levels.  A 1.53 fold decrease in proform and 4.23 
fold increase in cleaved caspase 9 was observed in Jurkat cells treated with anti-Fas 
antibody, which was used as a positive control for caspase 9 cleavage.  In BxPC3, 
MiaPaCa2, and Panc-1 cell lines, a decrease in proform and increase in cleaved caspase 9 
was observed upon treatment with TRAIL alone.  Further increase in 
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Figure 12. Caspase 9 activation in BxPC3, MiaPaCa2, and Panc-1 cell lines. 
Activation of caspase 9 in BxPC3, MiaPaCa2 and Panc-1 cell lines upon treatment with 
vehicle (V), 5 μM BITC 24 hours (B), 10 ng/ml TRAIL (T) for 6 hours or both BITC and 
TRAIL  Total  treatment  time was  24 hours.  Whole  cell lysates  were collected  and 
separated through SDS-PAGE, and Western blotting was performed as  described in 
the Methods and Materials.  Arrows indicated procaspase 9 and the active fragment.  
The blot was probed with active caspase 9 antibody and reprobed with pan actin used as a 
loading control. 
 This graph illustrates relative fold change in caspase 9 proform and cleaved 
caspase 9 protein levels in A. BxPC3, B. MiaPaCa2 and C. Panc-1 cell lines upon 
treatment with vehicle, BITC alone, TRAIL alone, or BITC combined with TRAIL.  Fold 
change was determined using NIH image analysis of a Western blot for caspase 9 




Figure 12.  
 47
caspase 9 cleavage was observed upon treatment with BITC combined with TRAIL in all 
three cell lines. 
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Activation of caspase 3 in BxPC3, MiaPaCa2, and Panc-1 cell lines  
   Because both the extrinsic and intrinsic cell death pathways trigger effector 
caspase cleavage, we analyzed for the effect of BITC and TRAIL on the major effector 
caspase, caspase 3 (Fig. 13).  The 32 kDa caspase 3 proform and the 17 kDa cleaved form 
were analyzed using NIH image to quantitate changes in protein level upon treatment 
with vehicle, BITC alone, TRAIL alone and BITC combined with TRAIL in BxPC3, 
MiaPaCa2 and Panc-1 cells.  In BxPC3 cells, BITC alone led to a fold change in caspase 
3 proform compared to vehicle.  TRAIL alone led to a 3.57 fold decrease and BITC 
combined with TRAIL led to a 2.37 fold decreases in caspase 3 proform.  BITC alone 
produced to a 0.91 fold increase in cleaved caspase 3.  TRAIL alone produced 5.43 fold 
increase and BITC combined with TRAIL produced a 9.83 fold increase in cleaved 
caspase 3 levels.  In MiaPaCa2 cells, BITC alone led to a 1.39 fold decrease in caspase 3 
proform.  TRAIL alone led to a 7.20 fold decrease and BITC combined with TRAIL led 
to a 5.25 fold decrease in caspase 3 proform.  BITC alone produces a 2.11 fold increase 
in cleaved caspase 3.  TRAIL alone produced a 2.11 fold increase and BITC combined 
with TRAIL produced a 8.21 fold increase in cleaved caspase 3.  In Panc-1 cells, BITC 
alone produced a 1.47 fold decrease fold decrease in caspase 3 proform.  TRAIL alone 
led to a 1.65 fold decrease and BITC combined with TRAIL led to a 1.23 fold decrease in 
caspase 3 proform.  BITC alone produced a 0.34 fold increase in cleaved caspase 3.  
TRAIL alone produced a 1.87 fold increase and a 2.92 fold increase in cleaved caspase 3 
levels.  A 4.80 fold decrease in proform and a 5.85 fold increase in cleaved caspase 3  
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Figure 13.  Caspase 3 activation in BxPC3, MiaPaCa2, and Panc-1 cells.  
 Cleavage of effector caspase 3 in BxPC3, MiaPaCa2 and Panc-1 cell lines upon 
treatment with vehicle (V), 5 μM BITC 24 hours (B), 10 ng/ml TRAIL (T) for 6 hours or 
both B and T.  Total treatment time was 24 hours.  Whole cell lysates were collected and 
separated through SDS-PAGE, and Western blotting was performed as described in the 
Methods and Materials.  The same blot was probed with pan actin used as a loading 
control 
 This graph illustrates relative fold change in caspase 3 proform and cleaved 
caspase 3 protein levels in A. BxPC3, B. MiaPaCa2 and C. Panc-1 cell lines upon 
treatment with vehicle, BITC alone, TRAIL alone, or BITC combined with TRAIL.  Fold 
change was determined using NIH image analysis of a Western blot for caspase 3 
normalized to the vehicle.  NIH image was developed by NIH and can be found at 
http://rsb.info.nih.gov/nih-image/. 
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Figure 13.    
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was observed in Jurkat cells treated with an anti-Fas antibody, which was used as a 
positive control for caspase 3 cleavage.  In BxPC3, MiaPaCa2, and Panc-1 cell lines, 
combined treatment with BITC and TRAIL increased cleaved caspase 3 levels compared 
to TRAIL alone.  
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PARP cleavage in BxPC3, MiaPaCa2, and Panc-1 cell lines  
 To confirm the activation of caspase 3 we examined PARP, a direct specific 
substrate of activated caspase 3 (Fig 14).  NIH image was used to quantify changes in the 
89 kDa cleaved PARP levels upon treatment with vehicle, BITC alone, TRAIL alone and 
BITC combined with TRAIL in BxPC3, MiaPaCa2 and Panc-1 cells.  In BxPC3 cells, 
BITC alone produced a 0.38 fold increase in cleaved PARP.  TRAIL alone produced a 
0.96 fold increase and BITC combined with TRAIL produced a 2.58 fold increase in 
cleaved PARP compared to vehicle.  In MiaPaCa2 cells, BITC alone led to a 4.17 fold 
increase in cleaved PARP.  TRAIL alone produced a 7.90 fold increase and BITC 
combined with TRAIL produced a 8.52 fold increase in   cleaved PARP.  In Panc-1 cells, 
BITC alone produced a 0.50 fold increase in cleaved PARP.  TRAIL alone produced a 
1.09 fold increase and BITC combined with TRAIL produce 1.12 fold increase fold 
increase in PARP cleavage.  A 1.75 fold increase in cleaved PARP was observed in 
Jurkat cells treated with a Fas receptor inducing antibody, which was used as a positive 
control for PARP cleavage.  In BxPC3 and MiaPaCa2 there was increased PARP 
cleavage upon treatment with BITC combined with TRAIL compared to TRAIL alone.  
A modest increase in cleaved PARP levels was observed in Panc-1 cells treated with 
BITC combined with TRAIL versus TRAIL alone. 
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Figure 14.  PARP cleavage in BxPC3, MiaPaCa2, and Panc-1 cells.  PARP cleavage 
and inactivation in BxPC3, MiaPaCa2 and Panc-1 cell lines upon treatment with vehicle 
(V), 5  μM BITC 24 hours (B), 10 ng/ml TRAIL (T) for 6 hours or both B and T.  Total 
treatment time was 24 hours.  Whole cell lysates were collected and separated through 
SDS-PAGE, and Western blotting was performed as described in the Methods and 
Materials.  The blot was probed with PARP antibody and reprobed with pan actin to 
ensure equal loading. 
 This graph illustrates relative fold change in cleaved PARP protein levels in 
BxPC3, MiaPaCa2 and Panc-1 cell lines upon treatment with vehicle, BITC alone, 
TRAIL alone, or BITC combined with TRAIL.  Fold change was determined using NIH 
image analysis of a Western blot for PARP normalized to the vehicle.  NIH image was 











IV.  DISCUSSION 
 
 
 Pancreatic cancer is a one of the leading causes of death in the United States.  
Chemotherapeutic resistance and high mortality in pancreatic cancer are associated with 
point mutations within codon 12 of K-Ras (61,69).  K-Ras regulates cellular proliferation 
in most cell types and mutations within codon 12 disrupt the normal on-off cycling, 
leading to constitutive signaling and proliferation (19).  This study determined whether 
the cell cycle inhibitor, BITC, could sensitize pancreatic adenocarcinomas with mutated 
K-Ras to TRAIL-induced apoptosis. 
 
Determination of optimal TRAIL dosage and treatment period 
 The Cell Death ELISA assay was used to quantitate apoptotic death in the 
pancreatic adenocarcinoma cell lines.  We determined that 10 ng/ml TRAIL for 6 hours 
was the optimal treatment to induce apoptosis in Panc-1 cells.  The time course ELISA 
interestingly showed a gradual decline in apoptosis from 6 hours to 24 hours (Fig. 4).  
Previous studies in our lab have shown that cells in culture can undergo secondary 
necrosis with extended treatment periods with cell death inducers (56).  The observed 
decrease in cell death is likely a result of secondary necrosis which was not detected 
because the Cell Death ELISA assay can exclude necrotic death and specifically measure 
apoptotic death.  K-Ras 12 wildtype BxPC3 cells were very sensitive to TRAIL-induced 
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apoptosis compared to resistant codon 12 K-Ras mutated Panc-1 cells.  This may be 
attributed to their K-Ras mutations, in that BxPC3 cells are K-Ras 12 WT and Panc-1 
cells are K-Ras 12 mutant. 
 
Apoptotic effects of BITC and TRAIL 
 We next observed the effect of BITC and TRAIL in BxPC3, MiaPaCa2, and 
Panc-1 cells.  In BxPC3, MiaPaCa2, and Panc-1 cell lines, BITC alone produced a 
minimum amount of apoptosis.  This result is unsurprising as we intentionally treated 
with low doses of BITC to minimize apoptotic death from BITC alone.  BITC is being 
used to sensitize the cells to TRAIL, which is tumor preferential unlike BITC.  TRAIL 
induced a greater fold increase of apoptotic death as indicated by Cell Death ELISA in 
BxPC3 and MiaPaCa2 cells than in Panc-1 cells.  The high levels of apoptosis in K-Ras 
12 gly cys, MiaPaCa2 cells and the low levels of apoptosis in K-Ras 12 gly asp Panc-
1 cells illustrates that the type of K-Ras 12 mutation may be crucial to the degree of 
TRAIL resistance as Panc-1 cells (K-Ras 12 gly asp) are more resistant than MiaPaCa2 
cells (K-Ras 12 gly cys).  In Panc-1 cells, between TRAIL alone and BITC with 
TRAIL, there is an increase in apoptosis.  However, combined treatment of BITC and 
TRAIL, appears to decrease apoptosis in BxPC3 and MiaPaCa2 cells, which contradicts 
increased cleavage of key apoptotic proteins observed in Western blot analysis.  
Therefore, further analysis was done on the inhibitory effects of BITC and TRAIL on cell 





Inhibitory effects of BITC and TRAIL on cell growth 
 Initial Cell Death ELISA results showed that BITC combined with TRAIL 
decreased apoptotic death compared to TRAIL alone.  However, observations in cell 
culture and with Western blot analysis of key apoptotic proteins led us to further explore 
these results.  Upon further analysis, the decrease in apoptosis seen in cells treated with 
both BITC and TRAIL could be a result of BITC halting cell division.  Previous studies 
have reported BITC functions through cell cycle arresting in pancreatic adenocarcinoma 
cell lines (25,36-40).  BITC inhibited cell growth in BxPC3 and MiaPaCa2 cells nearly 
1.5 times more than in Panc-1 cells.  This could be related to the growth rate of these 
cells.  BxPC3 cells have a doubling rate of 24 hours, MiaPaCa2 cells have a doubling rate 
of 19 hours, and Panc-1 cells have a doubling rate of 52 hours (70,71).  The cell cycle 
inhibiting effects of BITC were not fully apparent in Panc-1 cells, possibly due to a 
slower division rate.  The cells that divided more rapidly such as the BxPC3 and 
MiaPaCa2 cells were more prone to BITC's effects.  Although initially seeded at equal 
cell numbers, groups treated with BITC had less cells compared to groups treated with 
vehicle or TRAIL alone.  Since fewer cells were present to undergo apoptosis in the 
BITC combined with TRAIL treatment group as compared to TRAIL alone, the fold 
increase in apoptosis would appear to be lower than actual.  To correct for this, the 





Apoptotic death normalized to cell growth inhibition 
 The cell counts for BxPC3, MiaPaCa2 and Panc-1 cell lines reveal that the BITC 
treatments did impact cellular proliferation, confirming previous studies (39,63).  When 
the Cell Death ELISA assay results were normalized to cell number, the data indicated 
that BITC significantly sensitizes all three human pancreatic cancer cell lines to TRAIL-
induced apoptosis.  BxPC3 cells underwent the greatest degree of apoptosis, as expected, 
as they are K-Ras 12 wild type.  The K-Ras 12 mutant MiaPaCa2 cells had similar levels 
of apoptotic death.  This suggests that the K-Ras 12 (gly cys) mutation seen in 
MiaPaCa2 cells may not be dominant for chemotherapeutic resistance.  Alternatively, 
there are likely to be several different mutations in these cell lines that in combination 
may determine overall resistance.  Panc-1 cells were resistant to TRAIL-induced 
apoptosis but could be sensitized to TRAIL when treated in combination with BITC.  The 
normalized Cell Death ELISA indicates that BITC is sensitizing mutant K-Ras 12 cancer 
cell lines to TRAIL-induced apoptosis.    
 
Western Blot Analysis 
Caspase 8 activation 
 Activation of caspase 8 was observed, as TRAIL is reported to signal through the 
death receptor pathway (72).  For all three cell lines, overall there was a general decrease 
in caspase 8 proform levels going from vehicle, to BITC alone, to TRAIL alone and 
finally to BITC combined with TRAIL.  BITC alone caused a substantial decrease in 
caspase 8 proform in BxPC3 cells but minimal change in MiaPaCa2 and Panc-1 cells, 
which could be because BxPC3 are K-Ras 12 WT.  Interestingly, BxPC3 cells exhibited 
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minimal change in cleaved caspase 8 levels between TRAIL and BITC combined with 
TRAIL.  This was unexpected as Cell Death ELISA results indicate these cells to be 
TRAIL sensitive and high levels of caspase 8 cleavage would be expected with TRAIL, 
which signals through the extrinsic cell death pathway.  However, it may be that the high 
levels of apoptosis seen in BxPC3 cells are a result of increased activation downstream of 
caspase 8, such as through the intrinsic cell death pathway.  The increased cleavage in 
MiaPaCa2 and Panc-1 cells suggests that BITC is sensitizing to TRAIL-induced 
apoptosis as early as initiator caspase 8.   
 
XIAP cleavage 
 As a target of caspase 8, XIAP was examined (73,74).  XIAP is an important 
prosurvival protein and its inactivation by caspase cleavage could allow for increased 
levels of apoptosis.  XIAP levels had an overall decrease in BxPC3, MiaPaCa2, and 
Panc-1 cell lines going from vehicle, to BITC alone, to TRAIL alone, to BITC combined 
with TRAIL concurrently there was a substantial increase in the amount of XIAP cleaved 
in MiaPaCa2 and Panc-1 cells compared to BxPC3 cells.  This with the normalized Cell 
Death ELISA results suggests that BITC may be sensitizing to TRAIL-induced apoptosis 
in the resistant K-Ras 12 mutant Panc-1 cells by decreasing XIAP levels.  In MiaPaCa2 
and Panc-1 cell lines, there is less XIAP cleavage with TRAIL alone compared to BITC 
alone, which supports research that has indicated TRAIL-resistance is related to 
maintained high levels of XIAP.  High levels of XIAP have been implicated in TRAIL-
resistance in pancreatic cancer cells previously.  In MiaPaCa2 and Panc-1 cells, XIAP 
levels remained fairly constant compared to vehicle despite treatment with TRAIL.  
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However, upon treatment with BITC, XIAP levels are reduced and the Cell Death ELISA 
confirms increased apoptosis.  One mechanism by which BITC is overcoming TRAIL 
resistance could be by inactivated prosurvival XIAP.     
  
Bid cleavage 
 Bid cleavage was studied as it is also a direct target of caspase 8 and its truncated 
form can initiate the intrinsic cell death pathway (54).  In BxPC3, MiaPaCa2, and Panc-1 
cell lines there is a decrease in intact Bid levels between vehicle, BITC alone, TRAIL 
alone, and BITC combined with TRAIL.  In both BxPC3 and MiaPaCa2 cells, there was 
a dramatic drop in Bid levels upon treatment with TRAIL alone compared to the gradual 
decrease of Bid levels observed in Panc-1 cells.  This Bid truncation indicates that 
TRAIL is inducing both the extrinsic (death receptor) pathway but also suggests 
activation of the intrinsic (mitochondrial pathway).  Initiation of apoptosis by dual 
apoptotic proteins could increase levels of apoptosis.  The gradual loss of Bid in Panc-1 
cells also illustrate that of these three cell lines, Panc-1 cells are the most resistant to 
TRAIL-induced apoptosis.  The resistance seen in Panc-1 cells compared to the other cell 
lines evaluated may suggest that particular K-Ras 12 mutations may be associated with 
different levels of chemotherapeutic resistance.  The complete loss of Bid observed with 
combined treatment of BITC with TRAIL suggests that BITC is sensitizing to TRAIL-





Caspase 9 activation 
 Truncated Bid can lead to the activation of the intrinsic cell death pathway and 
caspase 9 (35).  Caspase 9 activation was analyzed to determine the involvement of the 
intrinsic cell death pathway.  All three cell lines showed an increase in cleaved caspase 9 
going from vehicle, to BITC alone, to TRAIL alone, to BITC combined with TRAIL.  
Cleavage of caspase 9 confirms activation of the intrinsic cell death pathway.  The most 
dramatic change was seen in BxPC3 cells, which supports these cells being TRAIL-
sensitive.  Interestingly, MiaPaCa2 cells showed only moderate increase in caspase 9 
cleavage despite high levels of apoptosis observed in the Cell Death ELISA.  However, 
this may be due to a cell specific pathway preference, meaning these cells may have 
preference of signaling from caspase 8 directly to caspase 3.  This idea supported because 
despite low levels of caspase 9 cleavage, there are still high levels of caspase 3 cleavage 
and high levels of apoptosis as indicated by the cell death ELISA.  Further analysis would 
be needed to confirm this pathway preference.  Increased caspase 9 cleavage could be 
due to increased caspase 8 cleavage but BITC may be increasing cleavage by another 
mechanism.  Previous research has shown BITC to increase the formation of ROS, which 
are capable of destabilizing the mitochondrial membrane (75).  This may make the 
mitochondria more susceptible to other apoptotic stimuli and allow for increased TRAIL-
induced apoptosis through the intrinsic cell death pathway.   
 
Caspase 3 activation 
 Both the extrinsic and intrinsic cell death pathway lead to the activation of the 
main effector caspase, caspase 3 (35,55-60).  In BxPC3, MiaPaCa2, and Panc-1 cells, 
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there was an overall decrease in caspase 3 inactive, proform levels from vehicle, to BITC 
alone, to TRAIL alone, and to BITC combined with TRAIL.  For all cell lines, there was 
a gradual increase in cleaved caspase 3 levels.  BxPC3 cells exhibited the greatest amount 
of caspase 3 cleavage, which supports these cells as being TRAIL-sensitive.  MiaPaCa2 
cells showed only slightly less cleavage of caspase 3 cleavage compared to BxPC3 cells.  
This is surprising as these cells are mutant K-Ras 12 and would therefore be expected to 
be TRAIL resistant.  However, it may be that the type of amino acid change at K-Ras 12 
is determinate of the level of chemotherapeutic resistance.  Panc-1 cells as expected were 
resistant to TRAIL-induced cleavage of caspase 3, which suggests that the K-Ras 12 
gly asp mutation may greatly increase chemotherapeutic resistance compared to the K-
Ras 12 gly  cys mutation in MiaPaCa2 cells.  However further study would be needed 
as there are many other different mutations in these cell lines that could interfere with 
response to chemotherapeutics.  The levels of caspase 3 correspond to the levels of 
apoptosis observed in the normalized Cell Death ELISA. 
 
PARP cleavage 
 Western blot analysis of cleaved PARP, a direct target of caspase 3, indicates the 
degree of caspase 3 activation.  In BxPC3, MiaPaCa2, and Panc-1 cells, an increase in 
PARP cleavage was observed going from vehicle, to BITC alone, to TRAIL alone, to 
BITC combined with TRAIL.  BxPC3 showed only moderate levels of PARP cleavage 
compared to the other cell lines, which is surprising as these cells are TRAIL-sensitive as 
indicated by high levels of caspase 3 activation and high levels of apoptosis as indicated 
by the Cell Death ELISA assay but these cells may have lower levels of PARP overall.  
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Interestingly, BITC alone substantially increased PARP cleavage in MiaPaCa2 cells, 
which conflicts with observed levels of caspase 3 cleavage.  However, it may be that 
MiaPaCa2 cells have higher levels of PARP, which is unknown as only cleaved PARP 
was observed.  Alternatively, the high levels of PARP cleavage may be attributed to 
cleavage by caspase 7, which can act in a similar manner as caspase 3.  Panc-1 cells 
showed levels of cleaved PARP consistent to levels of caspase 3 activation.  Cleavage of 
PARP, a known DNA repair enzyme, can leave cells less capable of repairing DNA 
damage and allow for apoptotic cell death.     
 Overall, NIH image analysis of Western blots for caspase 8, XIAP, Bid, caspases 
9 and 3 and PARP confirm protein changes observed and support BITC combined with 
TRAIL increases cleavage of these proteins compared to TRAIL alone.  These data taken 
together support the fact that BITC is sensitizing chemotherapeutically resistant 
pancreatic cancer cells to TRAIL-induced apoptosis.    
 
Summary of findings 
 In conclusion, our results indicate that BITC sensitizes BxPC3, MiaPaCa2, and 
Panc-1 cells to TRAIL-induced apoptosis via dual apoptotic pathways and by inducing 
several key apoptotic proteins, namely caspases 8, 9 and 3 as well as there respective 
substrates XIAP, Bid and PARP.  Results also show Panc-1 cells to be more resistant to 
TRAIL than BxPC3 and MiaPaCa2 cells, suggesting that certain K-Ras 12 mutations lead 
to increased TRAIL resistance, however further studies will be needed to confirm this 
observation.  Our data suggests that BITC may be of value for the treatment of 
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chemotherapeutically-resistant mutant K-Ras 12 pancreatic adenocarcinomas and 
possibly other mutant K-Ras 12 tumors as well. 
 
Future research 
 Panc-1 cells with a gly asp K-Ras 12 mutation show a higher resistance to 
TRAIL induced apoptosis even with combined BITC and TRAIL treatment.  The 
possibility exists that the gly asp mutation leads to increased resistance to apoptosis. 
 This could be tested in several ways.  The simplest of which would be to study 
TRAIL induced apoptosis in other pancreatic cancer cell lines with a K-Ras 12 gly asp 
mutation.  ASPC-1 cells are another pancreatic cancer with a K-Ras 12 gly asp   and 
would be ideal for this study.  Another possible method, would be to point mutate a K-
Ras 12 gly asp mutation into a K-Ras 12 WT pancreatic adenocarcinoma cell line such 
as BxPC3.  By using this method, all other mutations within the line would be unaffected 
and therefore any observations made would truly reflect the effects of the different K-Ras  
mutations.  When using different cell lines, there are several other mutations that are 
different between each line that could potentially change levels of TRAIL sensitivity.  
Determining the effect of varying K-Ras 12 mutations or chemotherapeutic resistance 
could shed light on improved treatment methods for a largely untreatable disease. 
 K-Ras 12 mutations have been indicated in numerous other high impact cancers 
such as lung cancer, which is the leading cause of cancer related death in the United 
States, and colon cancer (3,4,17,76).  In pancreatic cancer, there is a strong correlation to 
chemotherapeutic resistance with the presence of mutated K-Ras.  These same mutations 
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may play a similar role in treatment resistance of other cancers.  Again, it would be 
important to determine if specific K-Ras 12 mutations are related to varying resistance. 
 Although K-Ras is largely associated with the aggressiveness and 
chemotherapeutic resistance in pancreatic genes, other alterations within P53, Smad4, 
and PI3K signaling have been implicated in tumor invasiveness and resistance (12,77,78).  
PI3K is an upstream regulator of NF- KB, which has been implicated in 
chemotherapeutic resistance in pancreatic cancer (49,50).  NF-KB can upregulate the 
expression of XIAP, which is a prosurvival factor (79).  Previous research has indicated 
that TRAIL resistance in pancreatic cancer is partially attributed to both XIAP and NF-
KB (49,50).  RNA interference of XIAP and NF-KB has been shown to increase TRAIL 
sensitivity in resistant pancreatic cancer cell lines (49,50).  Although it is known that Ras 
signals through PI3K and subsequently NF-KB, it is not yet known that this is the 
pathway by which K-Ras mediates chemotherapeutic resistance.  PI3K is downstream of 
Ras and it may be possible that K-Ras mutations and/or mutations within PI3K are 
involved in resistance mediated by NF-KB.  Ras signals through PI3K to regulate NF-
KB, which in turn upregulates expression of XIAP, which is a prosurvival factor and is 
capable of inhibiting caspases (80,81).  K-Ras 12 mutations may contribute to resistance 
of XIAP cleavage, which has been observed in previous studies as well as this one (49).  
This may occur by increased signaling through PI3K, which is an upstream modulator of 
NF-KB and subsequently XIAP (80,81). 
 As a continuation of this project, PI3K and NF-KB should be studied to determine 
if they are in fact involved in the resistance seen in K-Ras 12 mutated cells.  BxPC3 (K-
Ras 12 WT), MiaPaCa2 (K-Ras 12 gly cys), and Panc-1 (K-Ras 12 gly asp) cell lines 
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would be ideal to use as they represent common K-Ras 12 mutations and range from 
being TRAIL-sensitive to TRAIL-resistant.  In this study, it appeared that BITC led to a 
greater decrease of XIAP levels in both MiaPaCa2 and Panc-1 cells than TRAIL did.  If 
this is confirmed, this may reveal how BITC is sensitizing these cells and in the following 
experiments BITC should be tested to observe any inhibition of PI3K and NF-KB, which 
would decrease XIAP levels.  NF-KB activity levels should be analyzed using a Trans-
AM ELISA for p50 and p65 NF-KB in the presence of vehicle, BITC alone, TRAIL 
alone, BITC combined with TRAIL, a pan-NF-KB inhibitor alone, and finally the NF-KB 
inhibitor with TRAIL.  If BITC treatment reduces NF-KB activity, this would suggest 
that sensitization by BITC is a result of leading to the decrease of prosurvival XIAP.  If 
NF-KB is responsible for resistance, the NF-KB inhibitor should restore sensitivity in the 
resistant cell lines.  Higher NF-KB activity levels in the resistant cell lines would support 
its responsibility for the observed TRAIL resistance.  It also suggests that with further 
study, this may be the mechanism by which K-Ras 12 is modulating chemotherapeutic 
resistance.  To confirm this, the pathway needs to be traced back to K-Ras.  PI3K is the 
upstream modulator of NF-KB.  To determine PI3K's involvement in increased NF-KB 
activity and not some other modulation of NF-KB, a time course study of both PI3K and 
NF-KB by Western blot analysis would be required.  If PI3K is involved, Western Blot 
analysis should show PI3K activation before increased activity of NF-KB.  If PI3K 
activation is observed before NF-KB activation, then cells treated with a PI3K inhibitor 
such as LY294002 should show decreased levels of NF-KB activity and possibly 
decreased levels of XIAP.  Resistant cell lines should become TRAIL-sensitive upon 
treatment with a PI3K inhibitor, if this is how resistance is acquired.  This would be 
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determined by quantifying apoptosis by an assay such as the cell death ELISA.  This 
increased signaling through PI3K could be a result of K-Ras, however there are many 
other factors that stimulate this pathway.  If increased signaling was observed in the K-
Ras 12 mutant cell lines such as MiaPaCa2 or Panc-1 cells as compared to K-Ras 12 WT 
BxPC3 cells, this would further implicate K-Ras 12 as the initiating factor.  To confirm 
that the involvement of K-Ras 12 in increased PI3K signaling, further research would be 
needed.  If inhibition of K-Ras led to a decrease in PI3K signaling and subsequently 
restored TRAIL-sensitivity, this taken with the results of the above NF-KB and XIAP 
experiments could confirm that one way K-Ras 12 is modulating chemotherapeutic 
resistance is through PI3K.  K-Ras activity could be inhibited by knock down of K-Ras 
12 by viral tranfection of shRNA against the specific amino acid mutations observed in 
MiaPaCa2 and Panc-1.  Previous studies have successfully used adenoviral delivered K-
Ras sirna in lung cancer cells (82).  K-Ras 12 has been successfully inhibited by 
transfection of siRNA in previous studies (83).  However, shRNA would allow for a 
more stable knockdown of a gene and with an adenoviral delivery system can remain 
episomal to prevent permanent interference with the genome (84,85,86).  This should at 
minimum be carried out in the sensitive K-Ras 12 WT BxPC3 cells and the resistant K-
Ras 12 gly asp Panc-1 cells.  Cells should be treated with vehicle, TRAIL alone, a 
scrambled shRNA, a shRNA against K-Ras 12 G12D and TRAIL combined with shRNA 
against K-Ras 12 G12D.  Levels of K-Ras 12 observed by Western blot analysis would 
confirm if K-Ras was successfully knocked down.  Decreased levels of activated PI3K in 
the knockdowns would confirm that K-Ras 12 is modulating PI3K activity.  Apoptosis 
should be quantitated to determine if knockdown of K-Ras restored TRAIL-sensitivity in 
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the resistant Panc-1 cell line.  Taken together, information from these experiments could 
shed light as to how K-Ras 12 mutations confer TRAIL resistance and allow for the 



















K-Ras- Kirsten Ras 
N-Ras-Neuroblastoma Ras 
NF-Kb-Nuclear Factor kappa B 
OPG-osteoprotogerin 
PARP- Poly (ADP-ribose) polymerase (PARP) 
PBS-Phosphate Buffered Saline 
PI3K-Phosphoinositide 3-kinases 
SDS-PAGE-Sodium Dodecyl Sulfate-Polyacrylamide gel electrophoresis 
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TBS-Tris Buffered Saline 
TNF- Tumor Necrosis Factor 
TRAIL- TNF related Apoptosis Inducing Factor 
TGF-beta- Transforming Growth Factor beta  
Val-Valine 
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